Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer

PURPOSE: Extending adjuvant endocrine therapy (ET) beyond the standard 5 years offers added protection against late breast cancer recurrences in women with early-stage hormone receptor-positive (HR +) breast cancer. Little is known about treatment persistence to extended ET (EET) and the role that g...

Descripción completa

Detalles Bibliográficos
Autores principales: Foldi, Julia, Tsagianni, Anastasia, Salganik, Max, Schnabel, Catherine A., Brufsky, Adam, van Londen, G. J., Pusztai, Lajos, Sanft, Tara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314405/
https://www.ncbi.nlm.nih.gov/pubmed/37391697
http://dx.doi.org/10.1186/s12885-023-11104-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314405/
https://www.ncbi.nlm.nih.gov/pubmed/37391697
http://dx.doi.org/10.1186/s12885-023-11104-w

Ejemplares similares